Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Growing your passive income can make it much easier to live off your investments during your retirement years.

Why Dividend Growth Stocks Should Be Part of Your Retirement Plan

Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs.

Should AbbVie Inc. Have a Place in Your Dividend Portfolio?

AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients

AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids

Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? The post Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming?

Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming?

Bristol-Myers

Johnson & Johnson

Royalty Pharma

The Oracle of Omaha doesn't like pharma stocks for some reason.

Do Warren Buffett's Recent Moves Spell Doom for This Group of Stocks?

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one or more lines of systemic therapy This is the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton's tyrosine kinase inhibitor (BTKi) treatment for a pediatric patient population cGVHD is a rare condition that can occur in patients after receiving peripheral blood or bone marrow stem cell transplantation often related to blood cancer treatment IMBRUVICA was the first treatment approved in the U.S. in 2017 for adult patients with cGVHD after failure of one or more lines of systemic therapy NORTH CHICAGO, Ill. , Aug. 24, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

Exxon Mobil

Check out these three top dividend paying stocks in the stock market this week.

Top Stocks To Buy Now? 3 Dividend Paying Stocks To Watch Today

Genuine Parts

Altria

These companies have raised their payouts to shareholders throughout multiple recessions, military conflicts, and a global pandemic.

Want Passive Income? Invest In These 3 Dividend Kings

JPMorgan Chase & Co

Tapestry

After the volatility of early 2022 and the aggressive rate tightening by the Fed, there's a return of chatter about the “Great Rotation” – that is, a broad move among investors to reduce exposure to growth-oriented stocks and increase their positions in value stocks as well as bonds.

These 3 safe stocks yield more that 10-year Treasurys

FleetCor Technologies

Medtronic

Mitek Systems

Playa Hotels & Resorts

Toyota Motor

Given the unique circumstances associated with the Covid-19 pandemic, investors may want to take a step back from the crowd and consider the best bargain stocks to buy now. To be sure, several equity-based opportunities printed much red ink this year, presenting cheap prospects to consider.

The 7 Best Bargain Stocks to Buy Now

Inmode Ltd

These beaten-down stocks share a favorable outlook for their aesthetic segments.

Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?

Pfizer

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year.

AbbVie Vs. Pfizer: Impact Of The Inflation Reduction Act On Their Future

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM® Difference IRVINE, Calif. , Aug. 17, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM® difference.

Experience the JUVÉDERM® Difference with Allergan Aesthetics

Skyrizi and Rinvoq are performing exceptionally (expected to deliver $7.5 B sales this year). Neuroscience, aesthetics, and oncology are showing strong growth as well.

AbbVie: Outstanding Portfolio Performance Continues

AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira.

AbbVie: Still A Solid Buy After Modeling Sales To 2030

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into AbbVie Inc. (NYSE: ABBV). Throughout the first half of 2021, the Company promoted its drug product, Rinvoq, a Janus kinase (“JAK”) inhibitor for the treatment of rheumatoid arthritis (“RA”). During this time, the U.S. Food and Drug Administration (FDA) announced warnings resulting from

ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV

AmerisourceBergen

Quest Diagnostics

HCA Healthcare

Labcorp Holdings Inc

McKesson

Merck

Viatris

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

10 defensive stocks that can also provide you with growth and dividends over the long term

Becton, Dickinson and Co.

Cigna

DuPont de Nemours

Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their business cycle.

7 Blue-Chip Stocks That Will Survive 2022

Amcor Plc

Air Products and Chemicals

Franklin Resources

Caterpillar

Cincinnati Financial

Chevron

Federal Realty Investment Trust

Leggett & Platt

Realty Income Corp

Stanley Black & Decker

V.F.

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of August 4, 2022 represented all eleven Morningstar Sectors. Broker estimated top-ten net gains ranged 14.54%-40.69% topped by XOM & SWK.

Buy 4 S&P 500 August Dog Days Dividend Aristocrats

AstraZeneca

When the market is falling, this trio keeps rising.

3 Unstoppable Stocks That Don't Care About the Bear Market

Income investors have a lot to like about these stocks.

3 Unstoppable Dividend Stocks to Buy in August

It won't be able to rely on Humira for growth for much longer.

3 Reasons Why AbbVie Stock Could Be Approaching a Make or Break Moment

The 2022 bear market might not be over, with some blue-chip economists predicting a further 18% to 43% decline before we bottom. JNJ and ABBV are two defensive healthcare dividend kings, which are up in 2022, helping investors sleep well at night in these turbulent times.

Johnson & Johnson And AbbVie: 2 Great Dividend Aristocrats For What's Coming Next

The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.

News for AbbVie Stock (ABBV)